Taysha Gene Therapies Future Growth

Future criteria checks 2/6

Taysha Gene Therapies is forecast to grow earnings and revenue by 13.6% and 47.9% per annum respectively while EPS is expected to grow by 20.9% per annum.

Key information

13.6%

Earnings growth rate

20.9%

EPS growth rate

Biotechs earnings growth	24.6%
Revenue growth rate	47.9%
Future return on equity	n/a
Analyst coverage	Good
Last updated	27 May 2024

Recent future growth updates

Recent updates

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Apr 20

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21

Earnings and Revenue Growth Forecasts

NasdaqGS:TSHA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	44	-85	-63	-97	5
12/31/2025	6	-102	-107	-92	10
12/31/2024	12	-91	-105	-86	8
3/31/2024	14	-118	-76	-73	N/A
12/31/2023	15	-112	-80	-73	N/A
9/30/2023	14	-214	-52	-42	N/A
6/30/2023	10	-124	-62	-53	N/A
3/31/2023	7	-133	-85	-68	N/A
12/31/2022	3	-166	-113	-88	N/A
9/30/2022	N/A	-161	-174	-143	N/A
6/30/2022	N/A	-186	-179	-146	N/A
3/31/2022	N/A	-193	-168	-136	N/A
12/31/2021	N/A	-175	-139	-117	N/A
9/30/2021	N/A	-142	-116	-97	N/A
6/30/2021	N/A	-106	-87	-71	N/A
3/31/2021	N/A	-87	-61	-51	N/A
12/31/2020	N/A	-60	-40	-31	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TSHA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TSHA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TSHA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TSHA's revenue (47.9% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: TSHA's revenue (47.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TSHA's Return on Equity is forecast to be high in 3 years time

Taysha Gene Therapies Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 23%

Consensus revenue estimates increase by 25%

Price target increased by 7.9% to US$6.06

Consensus revenue estimates increase by 40%, EPS downgraded

Consensus estimates of losses per share improve by 33%

Price target decreased by 20% to US$5.77

Recent updates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Taysha Gene Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Taysha Gene Therapies, Inc., Annual General Meeting, May 29, 2024

Consensus revenue estimates increase by 23%

Consensus revenue estimates increase by 25%

Price target increased by 7.9% to US$6.06

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Taysha Gene Therapies, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Taysha: Produces Solid Data But Has Abandoned Programs

Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Board Observer recently bought US$163k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Taysha Gene Therapies, Inc. Announces Second Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

CFO & Corporate Secretary notifies of intention to sell stock

Taysha Gene Therapies, Inc. Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Consensus estimates of losses per share improve by 33%

Taysha Gene Therapies, Inc. announced that it expects to receive $149.952767 million in funding from a group of investors

Taysha Gene Therapies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities

Taysha Gene Therapies, Inc. Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Insider recently sold US$61k worth of stock

New minor risk - Insider selling

Insider recently sold US$308k worth of stock

Taysha Gene Therapies, Inc. Announces First Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc., Annual General Meeting, Jun 22, 2023

Taysha Gene Therapies, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 20% to US$5.77

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy

Price target decreased by 11% to US$14.57

Taysha Gene Therapies, Inc. Announces Separation Suyash Prasad as Chief Medical Officer

Price target decreased to US$15.36

Price target decreased to US$16.79

High number of new and inexperienced directors

Price target decreased to US$17.21

Taysha Gene Therapies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Price target decreased to US$22.46

Taysha Gene Therapies, Inc. announced that it expects to receive $50 million in funding from Astellas Pharma Inc.

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 2000 Growth Index

Chief Technical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome

Price target decreased to US$39.07

Taysha Gene Therapies Gets A 'Thumbs Up'

Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease At 18th Annual WORLDSymposium

Independent Director recently bought US$80k worth of stock

Taysha Gene Therapies, Inc. Reports Positive Clinical Efficacy and Safety Data for the High Dose Cohort of 3.5X10 Total Vg

Taysha Gene Therapies, Inc. Announces Positive Initial Biomarker Data for TSHA-101

High number of new and inexperienced directors

Taysha Gene Therapies, Inc Announces Plans to Provide Clinical Data Updates

Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design

Taysha Gene Therapies Announces Initiation of Clinical Development of Tsha-118 for the Treatment of Cln1 Disease

Independent Director recently bought US$251k worth of stock

Independent Director recently bought US$251k worth of stock

Insider notifies of intention to sell stock

Chief Technical Officer notifies of intention to sell stock